Michael Gold to Disease Progression
This is a "connection" page, showing publications Michael Gold has written about Disease Progression.
Connection Strength
0.191
-
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
Score: 0.069
-
A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013 May; 208(5):410.e1-6.
Score: 0.023
-
The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 2013 Feb; 128(2):265-70.
Score: 0.023
-
Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int J Cancer. 2013 Jan 01; 132(1):148-54.
Score: 0.022
-
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009 Nov 01; 125(9):2151-8.
Score: 0.019
-
Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer. 2009 Feb 15; 124(4):964-9.
Score: 0.018
-
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):113-20.
Score: 0.018